Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sudhir Tauro

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Haematologica|April 23, 2026
Recovering from a therapeutic stall in higher-risk myelodysplastic syndromes: re-examining biology, backbones and study designsSudhir Tauro, Ayalew Tefferi
Cell Communication and Signaling : CCS|June 14, 2023
Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibitionJosh T Coats, Sudhir Tauro, Calum Sutherland
British Journal of Haematology|April 2, 2005
Biology and management of relapsed acute myeloid leukaemiaCharles Craddock, Sudhir Tauro, Paul Moss, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|June 7, 2025
The enzyme glycogen synthase kinase-3 is associated with specific forms of oncogenesis; what more do we need to know to achieve clinical benefit?Calum Sutherland, Ruby Harrower, Josh T Coats, et al.
Blood Cancer Journal|August 7, 2021
The long shadow of socioeconomic deprivation over the modern management of acute myeloid leukemia: time to unravel the challengesM Joseph John, Philip Kuriakose, Mark Smith, et al.
Cancer Genetics|March 2, 2011
Factors influencing a second myeloid malignancy in patients with Philadelphia-negative -7 or del(7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemiaMichael J Groves, Mark Sales, Lee Baker, et al.
American Journal of Hematology|April 28, 2011
Predicted costs of iron-chelators in myelodysplastic syndromes: a 10-year analysis based on actual prevalence and red cell transfusion ratesSenthilkumar Durairaj, Stephen Chew, Ann Hyslop, et al.
Cancer Research Communications|October 29, 2024
Elraglusib Induces Cytotoxicity via Direct Microtubule Destabilization Independently of GSK3 InhibitionJosh T Coats, Shuyu Li, Tomoyuki U Tanaka, et al.
American Journal of Hematology|March 5, 2010
Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): a comparison of two adapted BFM protocolsSudhir Tauro, Lynda Cochrane, Grete Fossum Lauritzsen, et al.
FEBS Letters|October 13, 2010
Δ160p53 is a novel N-terminal p53 isoform encoded by Δ133p53 transcriptVirginie Marcel, Stéphane Perrier, Mustapha Aoubala, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Haematologica|April 23, 2026
Recovering from a therapeutic stall in higher-risk myelodysplastic syndromes: re-examining biology, backbones and study designsSudhir Tauro, Ayalew Tefferi
Cell Communication and Signaling : CCS|June 14, 2023
Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibitionJosh T Coats, Sudhir Tauro, Calum Sutherland
British Journal of Haematology|April 2, 2005
Biology and management of relapsed acute myeloid leukaemiaCharles Craddock, Sudhir Tauro, Paul Moss, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer|June 7, 2025
The enzyme glycogen synthase kinase-3 is associated with specific forms of oncogenesis; what more do we need to know to achieve clinical benefit?Calum Sutherland, Ruby Harrower, Josh T Coats, et al.
Blood Cancer Journal|August 7, 2021
The long shadow of socioeconomic deprivation over the modern management of acute myeloid leukemia: time to unravel the challengesM Joseph John, Philip Kuriakose, Mark Smith, et al.
Cancer Genetics|March 2, 2011
Factors influencing a second myeloid malignancy in patients with Philadelphia-negative -7 or del(7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemiaMichael J Groves, Mark Sales, Lee Baker, et al.
American Journal of Hematology|April 28, 2011
Predicted costs of iron-chelators in myelodysplastic syndromes: a 10-year analysis based on actual prevalence and red cell transfusion ratesSenthilkumar Durairaj, Stephen Chew, Ann Hyslop, et al.
Cancer Research Communications|October 29, 2024
Elraglusib Induces Cytotoxicity via Direct Microtubule Destabilization Independently of GSK3 InhibitionJosh T Coats, Shuyu Li, Tomoyuki U Tanaka, et al.
American Journal of Hematology|March 5, 2010
Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): a comparison of two adapted BFM protocolsSudhir Tauro, Lynda Cochrane, Grete Fossum Lauritzsen, et al.
FEBS Letters|October 13, 2010
Δ160p53 is a novel N-terminal p53 isoform encoded by Δ133p53 transcriptVirginie Marcel, Stéphane Perrier, Mustapha Aoubala, et al.
Pageof 3